A Phase 3 interventional study of pregabalin and placebo in Neuropathic Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 156 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing pregabalin in Neuralgia — 4 open to participants now, 4 under way, 1 of them phase 3. Pregabalin · Neuralgia.
Among the 50 studies testing pregabalin in Neuralgia, this one has the largest enrollment, is one of 3 that started in 2012, is one of 18 in phase 3, and was the 28th registered.
1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.
Browse Neuralgia studies →4 of the 50 studies testing pregabalin in Neuralgia are open now, in 4 countries. Recruiting first, the newest first:
Moumtzidou Maria Aikaterini · Sites in Greece
Ages 18+ · Women only
Brainfarma Industria Química e Farmacêutica S/A · Sites in Brazil
Ages 18–75
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–75
Helsinki University Central Hospital · Sites in Finland
Ages 18–75
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 19 · Phase 4 12
First in 2002; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 542 is above the median of 52 across 831 interventional studies indexed under Neuralgia.
Median enrollment 109 across the 50 interventional studies. Of the 35 that completed or were terminated, 10 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
25 studies in Neuralgia by Viatris Inc.: none open now, none under way, none of them phase 3. Of 23 finished, 17 (74%) have results posted.
Among the 25 studies in Neuralgia by Viatris Inc., this one has the largest enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2012, is one of 8 in phase 3, and was the 22nd registered.
Viatris Inc.’s Neuralgia studies by the year they started, since 2004.
2 of the studies testing pregabalin in Neuralgia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07712913Phase 3Brainfarma Industria Química e Farmacêutica S/AExtended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia | 2027-06-01 |
| NCT07880223Moumtzidou Maria AikateriniComparison of Two Postoperative Care Strategies After Breast Surgery | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 50 studies testing pregabalin in Neuralgia, from their registry updates:
Among Viatris Inc.’s 25 in Neuralgia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to investigate if pregabalin is effective in treating neuropathic (nerve) pain resulting from peripheral nerve trauma due to a traumatic or surgical event such as, for example, motor vehicle accident, fall, sports injury, knee or hip replacement, hernia repair, thoracotomy, mastectomy, focal/localized burns or crush injury.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pregabalin
Drug: placebo
capsules, 150-600 mg/day administered in divided doses twice a day for 15 weeks after randomization
Also known as: Lyrica, PD-144723
capsules, placebo for pregabalin administered in divided doses twice a day for 15 weeks after randomization
Baseline Mean Pain Score
This is based on the daily pain dairy and is defined as the baseline mean pain diary score. The Daily Pain Diary consists of an 11-point numeric rating scale (NRS) ranging from 0 ("no pain") to 10 ("worst possible pain"). Subjects describe their pain during the past 24 hours by choosing the appropriate number between 0 and 10.
Time frame: Baseline
Change From Baseline to Week 15 in Weekly Mean Pain Score
This is based on the daily pain diary and is defined as the change from baseline to week 15 in mean pain diary score. The Daily Pain Diary consists of an 11-point numeric rating scale (NRS) ranging from 0 ("no pain") to 10 ("worst possible pain"). Subjects describe their pain during the past 24 hours by choosing the appropriate number between 0 and 10.
Time frame: up to Week 15
Patient Global Impression of Change (PGIC) at Week 15
A self administered instrument that measures changes in participants' overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). The PGIC is based on the Clinical Global Impression of Change, which is a validated scale.
Time frame: Week 15
Change From Baseline in Overall Weekly Mean Sleep Interference Score (SIRS)
This is an 11-point NRS ranging from 0 ("pain does not interfere with sleep") to 10 ("pain completely interferes with sleep" \[unable to sleep due to pain\]). Participants describe how pain has interfered with their sleep during the past 24 hours. Please note that the data for Baseline (raw scores) have been included in the below table to read the change from Baseline data in context. Note: Weekly mean SIRS scores were derived from the daily sleep diary and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean SIRS scores were defined as the mean of the 7 daily diary SIRS scores from Day 2+7 (n-1) to Day 1+7\*n. For participants with multiple diary scores collected on the same day, the average of all non-missing scores for that day was used in any analyses or data listings. "Overall" is the pooled average sleep interference score for each subject across all post-baseline/randomization weeks.
Time frame: up to Week 15
Change From Baseline in Pain Severity Index (Brief Pain Inventory-short Form [BPI-sf])
A self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the 24 hour period prior to evaluation. The BPI-sf consists of 5 questions. Four items measure pain on 11-point response scales from 0 (No Pain) to 10 (Pain as bad as you can imagine). In the above scale, score 0 indicates the better outcome whereas score 10 indicates the worse outcome.
Time frame: Week 15
Change From Baseline in Pain Interference Index (BPI-sf)
BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the 24 hour period prior to evaluation. It consists of 7 sub-questions that evaluates the level of pain interference with daily functioning on 11-point response scales from 0 (does not interfere) to 10 (completely interferes). The BPI-sf pain interference index was calculated as average of the seven individual pain interference scores.
Time frame: Week 15
Change From Baseline to Endpoint in Quality of Life Using EuroQol (EQ-5D) Health State Profile Scores
A self-administered questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain/ discomfort, and anxiety/ depression. Each dimension is rated on a 3 point response scale and the scores are combined to form a single index value between 0 and 1 with higher scores being more positive (better health status). The EQ-5D was completed by the subject at week-0 and week-15/ET where 30% responder and 50% responder status would be defined for each participants based on the percent change from baseline (week 0/Randomization) to each visit week in mean pain score and participant global impression of change (PGIC). PGIC is a self-administered instrument that measures change in participant's overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). It is based on the Clinical Global Impression of Change CGIC), which is a validated scale.
Time frame: Week 15
Baseline Scores in the Medical Outcomes Study Sleep Scale (MOS-SS) - Sub-domain Score.
MOS-SS is a self administered measure consisting of twelve items that assess the key constructs of sleep. Instrument scored results in 7 subscales: sleep disturbance, snoring, awaken short of breath or with headache, quantity of sleep, optimal sleep, sleep adequacy, somnolence. Two index measures that assess sleep disturbance was also constructed to provide composite scores. Sleep disturbance, snoring, somnolence, awaken short of breath, and the 9 items sleep problems index all have score ranges from 0 (no sleep problems) to 100 (greater sleep problems), therefore a negative change indicates improvement. Sleep adequacy is scored 0 (least sleep adequacy) to 100 (better sleep adequacy), therefore a positive change indicates improvement. Quantity of sleep is scored 0 (less quantity of sleep) to 24 (greater quantity of sleep), therefore a positive change indicates improvement. Optimal sleep is scored Yes if average hours of sleep is in range of 7-8 hours.
Time frame: Baseline
Mean Change From Baseline in the Medical Outcomes Study Sleep Scale (MOS-SS) - Sub-domain Score.
MOS-SS is a self administered measure consisting of twelve items that assess the key constructs of sleep. Instrument scored results in 7 subscales: sleep disturbance, snoring, awaken short of breath or with headache, quantity of sleep, optimal sleep, sleep adequacy, somnolence. Two index measures that assess sleep disturbance was also constructed to provide composite scores. Sleep disturbance, snoring, somnolence, awaken short of breath, and the 9 items sleep problems index all have score ranges from 0 (no sleep problems) to 100 (greater sleep problems), therefore a negative change indicates improvement. Sleep adequacy is scored 0 (least sleep adequacy) to 100 (better sleep adequacy), therefore a positive change indicates improvement. Quantity of sleep is scored 0 (less quantity of sleep) to 24 (greater quantity of sleep), therefore a positive change indicates improvement. Optimal sleep is scored Yes if average hours of sleep is in range of 7-8 hours.
Time frame: Week 15
Percentage of Participants in MOS-SS With Optimal Sleep Status.
MOS-SS optimal sleep status analyzed on a scale of four parameters: any improvements, no change, any worsening and not applicable.
Time frame: Week 15
Percentage of Responders to Treatment With Pregabalin Measured as Reduction in Mean Pain Score of ≥30%.
Participants with at least 30% reduction in the mean pain score from baseline to each week. Weekly mean pain NRS scores are derived from the daily pain NRS and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean pain score is defined as the mean of the 7 daily diary pain ratings from Day 2+7\*(n-1) to Day 1+7\*n. At least 4 entries within the last 7 days are required to calculate a mean score. Scores range from 0 (no pain) to 10 (worst possible pain), with higher scored indicating increased pain.
Time frame: Week 15
Percentage of Responders to Treatment With Pregabalin Measured as Reduction in Mean Pain Score of ≥50%
Participants with at least 50% reduction in the mean pain score from baseline to each week. Weekly mean pain NRS scores are derived from the daily pain NRS and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean pain score is defined as the mean of the 7 daily diary pain ratings from Day 2+7\*(n-1) to Day 1+7\*n. At least 4 entries within the last 7 days are required to calculate a mean score. Scores range from 0 (no pain) to 10 (worst possible pain), with higher scored indicating increased pain.
Time frame: Week 15
A total of 187 centers participated in the study in 14 countries. During screening, with the exception of daily pain score data that was collected to determine participants eligibility, no participants were treated with active drug and no efficacy data were collected. Only safety and no efficacy data was collected during the taper period.
| Milestone | Pregabalin | Placebo |
|---|---|---|
| Started | 275 | 267 |
| Treated | 274 | 265 |
| Completed | 233 | 211 |
| Not completed | 42 | 56 |
| Withdrew: Adverse events not related to study drug | 1 | 6 |
| Withdrew: Adverse events related to study drug | 12 | 10 |
| Withdrew: Protocol violation | 5 | 3 |
| Withdrew: No longer willing to participate | 8 | 14 |
| Withdrew: Lost to follow-up | 6 | 9 |
| Withdrew: Insufficient clinical response | 6 | 6 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Randomized but not treated | 1 | 2 |
| Withdrew: Reasons other than those mentioned above | 3 | 5 |
This is based on the daily pain dairy and is defined as the baseline mean pain diary score. The Daily Pain Diary consists of an 11-point numeric rating scale (NRS) ranging from 0 ("no pain") to 10 ("worst possible pain"). Subjects describe their pain during the past 24 hours by choosing the appropriate number between 0 and 10.
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Baseline Mean Pain Score | 6.41 ± 1.30 | 6.54 ± 1.30 |
This is based on the daily pain diary and is defined as the change from baseline to week 15 in mean pain diary score. The Daily Pain Diary consists of an 11-point numeric rating scale (NRS) ranging from 0 ("no pain") to 10 ("worst possible pain"). Subjects describe their pain during the past 24 hours by choosing the appropriate number between 0 and 10.
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Change From Baseline to Week 15 in Weekly Mean Pain Score | -2.12 ± 0.15 | -1.90 ± 0.16 |
A self administered instrument that measures changes in participants' overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). The PGIC is based on the Clinical Global Impression of Change, which is a validated scale.
| Participants | Pregabalin | Placebo |
|---|---|---|
| Very much improved | 52 | 41 |
| Much improved | 105 | 79 |
| Minimally improved | 61 | 62 |
| No change | 34 | 51 |
| Minimally worse | 5 | 9 |
| Much worse | 0 | 4 |
| Very much worse | 1 | 0 |
This is an 11-point NRS ranging from 0 ("pain does not interfere with sleep") to 10 ("pain completely interferes with sleep" \[unable to sleep due to pain\]). Participants describe how pain has interfered with their sleep during the past 24 hours. Please note that the data for Baseline (raw scores) have been included in the below table to read the change from Baseline data in context. Note: Weekly mean SIRS scores were derived from the daily sleep diary and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean SIRS scores were defined as the mean of the 7 daily diary SIRS scores from Day 2+7 (n-1) to Day 1+7\*n. For participants with multiple diary scores collected on the same day, the average of all non-missing scores for that day was used in any analyses or data listings. "Overall" is the pooled average sleep interference score for each subject across all post-baseline/randomization weeks.
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Baseline (raw scores) (N = 274, 265) | 4.97 ± 2.30 | 4.99 ± 2.27 |
| Week 1 (N = 260, 258) | -0.66 ± 1.10 | -0.28 ± 0.91 |
| Week 2 (N = 254, 244) | -1.15 ± 1.51 | -0.81 ± 1.27 |
| Week 3 (N = 252, 245) | -1.55 ± 1.73 | -1.14 ± 1.45 |
| Week 4 (N = 245, 229) | -1.73 ± 1.80 | -1.30 ± 1.63 |
| Week 5 (N = 241, 226) | -1.87 ± 1.87 | -1.40 ± 1.68 |
| Week 6 (N = 244, 227) | -1.94 ± 1.95 | -1.46 ± 1.79 |
| Week 7 (N = 240, 216) | -2.01 ± 1.99 | -1.50 ± 1.78 |
| Week 8 (N = 236, 212) | -2.05 ± 2.00 | -1.52 ± 1.76 |
| Week 9 (N = 232, 214) | -2.09 ± 1.99 | -1.55 ± 1.86 |
| Week 10 (N = 229, 212) | -2.04 ± 2.11 | -1.55 ± 1.83 |
| Week 11 (N = 230, 211) | -2.09 ± 2.05 | -1.64 ± 1.79 |
| Week 12 (N = 227, 209) | -2.17 ± 2.06 | -1.68 ± 1.89 |
| Week 13 (N = 225, 204) | -2.19 ± 2.06 | -1.70 ± 1.90 |
| Week 14 (N = 222, 208) | -2.19 ± 2.16 | -1.79 ± 1.89 |
| Week 15 (N = 196, 186) | -2.13 ± 2.17 | -1.83 ± 1.87 |
| Overall (N = 269, 262) | -1.83 ± 1.93 | -1.37 ± 1.71 |
A self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the 24 hour period prior to evaluation. The BPI-sf consists of 5 questions. Four items measure pain on 11-point response scales from 0 (No Pain) to 10 (Pain as bad as you can imagine). In the above scale, score 0 indicates the better outcome whereas score 10 indicates the worse outcome.
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Change From Baseline in Pain Severity Index (Brief Pain Inventory-short Form [BPI-sf]) | -2.40 ± 0.13 | -1.95 ± 0.13 |
BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the 24 hour period prior to evaluation. It consists of 7 sub-questions that evaluates the level of pain interference with daily functioning on 11-point response scales from 0 (does not interfere) to 10 (completely interferes). The BPI-sf pain interference index was calculated as average of the seven individual pain interference scores.
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Change From Baseline in Pain Interference Index (BPI-sf) | -1.72 ± 0.13 | -1.33 ± 0.13 |
A self-administered questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain/ discomfort, and anxiety/ depression. Each dimension is rated on a 3 point response scale and the scores are combined to form a single index value between 0 and 1 with higher scores being more positive (better health status). The EQ-5D was completed by the subject at week-0 and week-15/ET where 30% responder and 50% responder status would be defined for each participants based on the percent change from baseline (week 0/Randomization) to each visit week in mean pain score and participant global impression of change (PGIC). PGIC is a self-administered instrument that measures change in participant's overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). It is based on the Clinical Global Impression of Change CGIC), which is a validated scale.
| Units on a scale | Pregabalin | Placebo |
|---|---|---|
| Mobility | -0.10 ± 0.03 | -0.09 ± 0.03 |
| Self-care | -0.08 ± 0.02 | -0.06 ± 0.02 |
| Usual activities | -0.12 ± 0.03 | -0.13 ± 0.04 |
| Pain/Discomfort | -0.35 ± 0.03 | -0.29 ± 0.04 |
| Anxiety/Depression | 0.01 ± 0.03 | -0.02 ± 0.03 |
| Dolan 1997 Index Score | 0.12 ± 0.01 | 0.11 ± 0.01 |
| Dolan 2001 Index Score | -0.13 ± 0.02 | -0.12 ± 0.02 |
MOS-SS is a self administered measure consisting of twelve items that assess the key constructs of sleep. Instrument scored results in 7 subscales: sleep disturbance, snoring, awaken short of breath or with headache, quantity of sleep, optimal sleep, sleep adequacy, somnolence. Two index measures that assess sleep disturbance was also constructed to provide composite scores. Sleep disturbance, snoring, somnolence, awaken short of breath, and the 9 items sleep problems index all have score ranges from 0 (no sleep problems) to 100 (greater sleep problems), therefore a negative change indicates improvement. Sleep adequacy is scored 0 (least sleep adequacy) to 100 (better sleep adequacy), therefore a positive change indicates improvement. Quantity of sleep is scored 0 (less quantity of sleep) to 24 (greater quantity of sleep), therefore a positive change indicates improvement. Optimal sleep is scored Yes if average hours of sleep is in range of 7-8 hours.
| Units on a scale | Pregabalin | Placebo |
|---|---|---|
| Sleep Disturbance Score (N = 274, 265) | 42.50 ± 25.791 | 43.75 ± 25.080 |
| Sleep Adequancy Score (N = 274, 265) | 40.0 ± 28.153 | 40.0 ± 28.582 |
| Snoring Score (N = 272, 263) | 20.0 ± 33.482 | 20.0 ± 34.084 |
| Awaken Short of Breath Score (N = 274, 265) | 0.0 ± 25.647 | 0.0 ± 21.541 |
| Quantity of Sleep Score (hours) (N = 273, 265) | 6.0 ± 1.360 | 6.0 ± 1.411 |
| Somnolence Score (N = 274, 265) | 26.67 ± 21.618 | 26.67 ± 19.884 |
| Sleep Problem Index (9) Score (N = 274, 265) | 40.56 ± 20.282 | 41.11 ± 19.720 |
| Optimal Sleep Score (N = 273, 265) | 0.0 ± 0.476 | 0.0 ± 0.487 |
MOS-SS is a self administered measure consisting of twelve items that assess the key constructs of sleep. Instrument scored results in 7 subscales: sleep disturbance, snoring, awaken short of breath or with headache, quantity of sleep, optimal sleep, sleep adequacy, somnolence. Two index measures that assess sleep disturbance was also constructed to provide composite scores. Sleep disturbance, snoring, somnolence, awaken short of breath, and the 9 items sleep problems index all have score ranges from 0 (no sleep problems) to 100 (greater sleep problems), therefore a negative change indicates improvement. Sleep adequacy is scored 0 (least sleep adequacy) to 100 (better sleep adequacy), therefore a positive change indicates improvement. Quantity of sleep is scored 0 (less quantity of sleep) to 24 (greater quantity of sleep), therefore a positive change indicates improvement. Optimal sleep is scored Yes if average hours of sleep is in range of 7-8 hours.
| Units on a scale | Pregabalin | Placebo |
|---|---|---|
| Sleep Disturbance Score (N = 257, 245) | -14.71 (-17.57 to -11.85) | -11.24 (-14.16 to -8.33) |
| Sleep Adequancy Score (N=257, 245) | 10.13 (6.49 to 13.76) | 8.16 (4.43 to 11.89) |
| Snoring Score (N = 257, 245) | -2.22 (-5.46 to 1.03) | -3.27 (-6.59 to 0.04) |
| Awaken Short of Breath Score (N = 257, 245) | -3.61 (-6.30 to -0.92) | -3.03 (-5.78 to -0.27) |
| Quantity of Sleep Score (hours) (N = 257, 245) | 0.42 (0.19 to 0.66) | 0.26 (0.03 to 0.50) |
| Somnolence Score (N = 257, 245) | -1.61 (-3.99 to 0.77) | -3.74 (-6.17 to -1.31) |
| Sleep Problem Index (9) Score (N = 257, 245) | -9.86 (-12.17 to -7.56) | -8.19 (-10.55 to -5.83) |
| Optimal Sleep Score (N = 256, 245) | 0.11 (0.05 to 0.18) | 0.04 (-0.03 to 0.10) |
MOS-SS optimal sleep status analyzed on a scale of four parameters: any improvements, no change, any worsening and not applicable.
| Percentage of participants | Pregabalin | Placebo |
|---|---|---|
| Any Improvements | 21.2 | 18.5 |
| No Change | 66.1 | 60.8 |
| Any Worsening | 6.2 | 13.2 |
| Not applicable | 6.6 | 7.5 |
Participants with at least 30% reduction in the mean pain score from baseline to each week. Weekly mean pain NRS scores are derived from the daily pain NRS and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean pain score is defined as the mean of the 7 daily diary pain ratings from Day 2+7\*(n-1) to Day 1+7\*n. At least 4 entries within the last 7 days are required to calculate a mean score. Scores range from 0 (no pain) to 10 (worst possible pain), with higher scored indicating increased pain.
| Percentage of participants | Pregabalin | Placebo |
|---|---|---|
| Week 1 (N = 260, 258) | 11.92 | 5.04 |
| Week 2 (N = 254, 244) | 27.17 | 20.08 |
| Week 3 (N = 252, 245) | 38.89 | 30.20 |
| Week 4 (N = 246, 229) | 41.87 | 34.50 |
| Week 5 (N = 241, 226) | 45.64 | 38.05 |
| Week 6 (N = 244, 227) | 48.77 | 41.41 |
| Week 7 (N = 240, 216) | 49.58 | 43.06 |
| Week 8 (N = 236, 213) | 50.42 | 46.48 |
| Week 9 (N = 232, 214) | 50.86 | 47.66 |
| Week 10 (N = 229, 212) | 52.84 | 47.17 |
| Week 11 (N = 231, 211) | 52.38 | 51.18 |
| Week 12 (N = 227, 209) | 54.63 | 52.63 |
| Week 13 (N = 226, 204) | 57.08 | 54.41 |
| Week 14 (N = 223, 208) | 57.40 | 54.33 |
| Week 15 (N = 196, 187) | 57.65 | 58.29 |
Participants with at least 50% reduction in the mean pain score from baseline to each week. Weekly mean pain NRS scores are derived from the daily pain NRS and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean pain score is defined as the mean of the 7 daily diary pain ratings from Day 2+7\*(n-1) to Day 1+7\*n. At least 4 entries within the last 7 days are required to calculate a mean score. Scores range from 0 (no pain) to 10 (worst possible pain), with higher scored indicating increased pain.
| Percentage of participants | Pregabalin | Placebo |
|---|---|---|
| Week 1 (N = 260, 258) | 4.62 | 2.33 |
| Week 2 (N = 254, 244) | 11.42 | 6.97 |
| Week 3 (N = 252, 245) | 22.62 | 13.47 |
| Week 4 (N = 246, 229) | 25.20 | 17.90 |
| Week 5 (N = 241, 226) | 28.22 | 19.47 |
| Week 6 (N = 244, 227) | 29.51 | 22.91 |
| Week 7 (N= 240, 216) | 30.42 | 22.22 |
| Week 8 (N = 236, 213) | 33.05 | 27.70 |
| Week 9 (N = 232, 214) | 34.05 | 26.17 |
| Week 10 (N = 229, 212) | 32.75 | 26.42 |
| Week 11 (N = 231, 211) | 34.20 | 25.59 |
| Week 12 (N = 227, 209) | 37.89 | 26.79 |
| Week 13 (N = 226, 204) | 35.84 | 27.45 |
| Week 14 (N = 223, 208) | 37.67 | 29.81 |
| Week 15 (N = 196, 187) | 39.80 | 34.22 |
Collected over From Day -21 to Day 112 (week 16) i.e. from baseline until 1 day post last taper dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin | — | 2/274 (0.7%) | 75/274 (27.4%) |
| Placebo | — | 7/265 (2.6%) | 33/265 (12.5%) |
| Event | Pregabalin | Placebo |
|---|---|---|
| HaemorrhoidsGastrointestinal disorders | 0/274 | 1/265 |
| ConcussionInjury, poisoning and procedural complications | 0/274 | 1/265 |
| OverdoseInjury, poisoning and procedural complications | 0/274 | 1/265 |
| Post procedural dischargeInjury, poisoning and procedural complications | 0/274 | 1/265 |
| Lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 0/274 | 1/265 |
| Major depressionPsychiatric disorders | 0/274 | 1/265 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/274 | 1/265 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 0/274 | 1/265 |
| Atrial fibrillationCardiac disorders | 1/274 | 0/265 |
| Urinary tract infectionInfections and infestations | 1/274 | 0/265 |
| Event | Pregabalin | Placebo |
|---|---|---|
| DizzinessNervous system disorders | 40/274 | 11/265 |
| SomnolenceNervous system disorders | 27/274 | 9/265 |
| NauseaGastrointestinal disorders | 14/274 | 8/265 |
| FatigueGeneral disorders | 14/274 | 10/265 |
| Age, Continuous(Years) | Pregabalin | Placebo | Total |
|---|---|---|---|
| Mean | 52.8 ± 12.9 | 53.4 ± 12.7 | 53.1 ± 12.8 |
| Age, Customized(Participants) | Pregabalin | Placebo | Total |
|---|---|---|---|
| 18 - 44 years | 59 | 61 | 120 |
| 45 - 64 years | 163 | 154 | 317 |
| >=65 years | 52 | 50 | 102 |
| Sex: Female, Male(Participants) | Pregabalin | Placebo | Total |
|---|---|---|---|
| Female | 132 | 134 | 266 |
| Male | 142 | 131 | 273 |
Showing the first 100 of 156 sites across 13 countries. Choose a country and city above to see the rest.
The record gives a start of Oct 2012, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2017, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →